In a precedential opinion, the Federal Circuit held that Teva's claims to methods of using humanized anti-CGRP antagonist antibodies to treat headache met both the written description and enablement requirements of § 112, because the claims cover the use of such antibodies for a specific therapeutic purpose rather than the antibody genus itself.
